Toenail fungal infection (onychomycosis) is often dismissed as a cosmetic concern. In people with diabetes, however, a thickened, brittle or deformed nail can press on adjacent skin, trap moisture, and create a break in the skin barrier on a foot that may not feel pain. This article reviews what recent systematic and narrative reviews show about how common nail disease is in diabetes, whether it raises ulcer risk, and how it can be treated safely.
How Common Is Onychomycosis in Diabetes?
A 2023 systematic review in Mycoses by Navarro Pérez and colleagues pooled 10 studies covering 5,664 people with diabetes. About 29% had onychomycosis, most often caused by Trichophyton rubrum. The condition was significantly associated with diabetic neuropathy and with higher glycated hemoglobin. A 2025 narrative review by Gupta and colleagues in Life cited a cohort in which onychomycosis was confirmed in 26% of people with diabetes compared with 9.1% of people without diabetes, with more mixed infections, including Candida and non-dermatophyte molds, in the diabetic group.
Risk factors identified across these reviews include older age, peripheral vascular disease, poor glycemic control, neuropathy, nail trauma and difficulty with foot hygiene. Reduced sensation and limited vision or flexibility can also delay recognition of nail changes.
Does Nail Disease Increase the Risk of Foot Ulceration?
The evidence here is mixed. The Navarro Pérez review found no statistically significant association between onychomycosis and ulceration (p = 0.185), and rated most included studies as low-level evidence. The authors described the literature as limited and inconsistent. By contrast, the review by Gupta and colleagues described tinea pedis and onychomycosis as predictors of foot ulceration in some studies and cited one analysis reporting higher odds of prior minor amputation among people with diabetes and onychomycosis (odds ratio 4.49).
These findings are best read together: nail disease is common and linked to neuropathy and hyperglycemia, which are themselves established ulcer risk factors, but whether onychomycosis independently causes ulcers has not been settled by high-quality prospective studies. Both reviews note that clinical appearance alone is unreliable, because thickened or discolored nails can result from trauma, psoriasis or reduced circulation. Laboratory confirmation, such as microscopy or culture, is therefore recommended before committing to long antifungal courses.
Treatment Considerations in People With Diabetes
Treatment choice is shaped by drug interactions and comorbidities. According to Gupta and colleagues, oral terbinafine is generally regarded as a first-line option and was not associated with hypoglycemia or significant interactions in one diabetic cohort. Itraconazole requires caution because of CYP3A4-mediated interactions, notably with simvastatin, and fluconazole can potentiate sulfonylureas. Because many people with diabetes take multiple medications, topical therapy is an attractive alternative for mild to moderate disease.
A 2025 scoping review in the Journal of Fungi by Gupta and colleagues examined topical efinaconazole 10% across patient groups. In diabetes, complete cure rates were modest, around 11% to 13% at one year, with mycological cure of about 58% in an open-label study. Efficacy did not correlate with HbA1c, and no systemic adverse effects were reported. The authors noted that visible nail improvement can lag behind mycological response, so treatment may need to continue beyond 48 weeks, and that treating coexisting tinea pedis was associated with better nail outcomes. Laser treatment was described as generally unsuitable in people with diabetes because of the risk of thermal injury in a neuropathic foot.
Nail Care as Part of Ulcer Prevention
The IWGDF 2023 guideline on preventing foot ulcers in diabetes (Bus and colleagues) emphasizes regular foot inspection, stratification of ulcer risk, and treatment of pre-ulcerative signs, supported by professional foot care in higher-risk categories. Nail disorders fit within this framework: thickened nails and ingrown edges can be identified at routine foot examination, and careful trimming by a trained clinician may reduce the chance of pressure or puncture injury. Treating tinea pedis and washing socks and towels at high temperatures may also lower reinfection, as noted in the 2025 review.
Key Takeaways
Roughly one in four to three people with diabetes has onychomycosis, and it is more frequent with neuropathy and higher HbA1c. Whether it directly raises ulcer risk remains uncertain, but nail changes are a visible marker of a foot that merits closer examination. Diagnosis should be confirmed with laboratory testing, and treatment selection should account for drug interactions with common diabetes and cardiovascular medications. Topical therapy is well tolerated but achieves modest complete-cure rates, so realistic expectations and prolonged follow-up are part of management.
References
- Navarro Pérez D, Tardaguila García A, García Oreja S, et al. Onychomycosis associated with diabetic foot syndrome: a systematic review. Mycoses. 2023;66(6):459-466.
- Gupta AK, Liddy A, Magal L, et al. Onychomycosis in diabetics: a common infection with potentially serious complications. Life (Basel). 2025;15(8):1285.
- Gupta AK, Taylor D, Dennis D, et al. Treating onychomycosis with efinaconazole: considerations for diverse patient groups. Journal of Fungi. 2025;11:843.
- Bus SA, Sacco ICN, Monteiro-Soares M, et al. Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2023 update). Diabetes Metabolism Research and Reviews. 2024;40(3):e3651.